nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—osteoarthritis—Prednisone—systemic scleroderma	0.701	1	CpDpCtD
Tolmetin—SLC22A6—Captopril—systemic scleroderma	0.0431	0.76	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—systemic scleroderma	0.0136	0.24	CbGbCtD
Tolmetin—PTGS2—skeletal joint—systemic scleroderma	0.00481	0.0984	CbGeAlD
Tolmetin—MPO—artery—systemic scleroderma	0.00444	0.0909	CbGeAlD
Tolmetin—MPO—endothelium—systemic scleroderma	0.00375	0.0768	CbGeAlD
Tolmetin—CXCL8—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.00366	0.0653	CbGpPWpGaD
Tolmetin—MPO—blood vessel—systemic scleroderma	0.00346	0.0708	CbGeAlD
Tolmetin—TDO2—lung—systemic scleroderma	0.00332	0.068	CbGeAlD
Tolmetin—CXCL8—smooth muscle tissue—systemic scleroderma	0.00277	0.0568	CbGeAlD
Tolmetin—PTGS1—artery—systemic scleroderma	0.00211	0.0431	CbGeAlD
Tolmetin—PTGS2—artery—systemic scleroderma	0.00201	0.0412	CbGeAlD
Tolmetin—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00197	0.624	CbGdCrCtD
Tolmetin—MPO—IL23-mediated signaling events—STAT4—systemic scleroderma	0.00183	0.0327	CbGpPWpGaD
Tolmetin—CXCL8—lung—systemic scleroderma	0.00183	0.0374	CbGeAlD
Tolmetin—PTGS1—endothelium—systemic scleroderma	0.00178	0.0364	CbGeAlD
Tolmetin—MPO—connective tissue—systemic scleroderma	0.00177	0.0363	CbGeAlD
Tolmetin—CXCL8—Spinal Cord Injury—AIF1—systemic scleroderma	0.00175	0.0313	CbGpPWpGaD
Tolmetin—PTGS2—endothelium—systemic scleroderma	0.0017	0.0348	CbGeAlD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—systemic scleroderma	0.0017	0.0303	CbGpPWpGaD
Tolmetin—PTGS1—blood vessel—systemic scleroderma	0.00164	0.0336	CbGeAlD
Tolmetin—MPO—skin of body—systemic scleroderma	0.0016	0.0328	CbGeAlD
Tolmetin—MPO—Folate Metabolism—CSF1—systemic scleroderma	0.00158	0.0282	CbGpPWpGaD
Tolmetin—PTGS2—blood vessel—systemic scleroderma	0.00157	0.0321	CbGeAlD
Tolmetin—TDO2—Monoamine Transport—IL1B—systemic scleroderma	0.00137	0.0245	CbGpPWpGaD
Tolmetin—MPO—digestive system—systemic scleroderma	0.00128	0.0262	CbGeAlD
Tolmetin—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00119	0.376	CbGdCrCtD
Tolmetin—MPO—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00119	0.0212	CbGpPWpGaD
Tolmetin—CXCL8—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00112	0.02	CbGpPWpGaD
Tolmetin—MPO—lung—systemic scleroderma	0.00107	0.0219	CbGeAlD
Tolmetin—CXCL8—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.00102	0.0182	CbGpPWpGaD
Tolmetin—Hepatitis—Pentoxifylline—systemic scleroderma	0.000934	0.00697	CcSEcCtD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000918	0.0164	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—MMP1—systemic scleroderma	0.00089	0.0159	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Mycophenolic acid—systemic scleroderma	0.000887	0.00662	CcSEcCtD
Tolmetin—Urinary tract infection—Mometasone—systemic scleroderma	0.000872	0.00651	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Leflunomide—systemic scleroderma	0.000871	0.0065	CcSEcCtD
Tolmetin—CXCL8—ATF4 activates genes—CCL2—systemic scleroderma	0.00086	0.0154	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000855	0.0153	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—CCL2—systemic scleroderma	0.000847	0.0151	CbGpPWpGaD
Tolmetin—Epistaxis—Mometasone—systemic scleroderma	0.000846	0.00632	CcSEcCtD
Tolmetin—PTGS1—connective tissue—systemic scleroderma	0.000841	0.0172	CbGeAlD
Tolmetin—Blood urea increased—Mycophenolate mofetil—systemic scleroderma	0.000825	0.00616	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Mycophenolic acid—systemic scleroderma	0.000804	0.006	CcSEcCtD
Tolmetin—PTGS2—connective tissue—systemic scleroderma	0.000804	0.0165	CbGeAlD
Tolmetin—Toxic epidermal necrolysis—Azathioprine—systemic scleroderma	0.000804	0.006	CcSEcCtD
Tolmetin—Haemolytic anaemia—Lisinopril—systemic scleroderma	0.000802	0.00599	CcSEcCtD
Tolmetin—Flatulence—Pentoxifylline—systemic scleroderma	0.000801	0.00598	CcSEcCtD
Tolmetin—Weight decreased—Captopril—systemic scleroderma	0.0008	0.00597	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL13—systemic scleroderma	0.000791	0.0141	CbGpPWpGaD
Tolmetin—CXCL8—PERK regulates gene expression—CCL2—systemic scleroderma	0.000785	0.014	CbGpPWpGaD
Tolmetin—Renal failure—Captopril—systemic scleroderma	0.000775	0.00578	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000772	0.0138	CbGpPWpGaD
Tolmetin—PTGS1—smooth muscle tissue—systemic scleroderma	0.000769	0.0157	CbGeAlD
Tolmetin—Stomatitis—Captopril—systemic scleroderma	0.000768	0.00574	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000768	0.0137	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	0.000767	0.0137	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—SELP—systemic scleroderma	0.000762	0.0136	CbGpPWpGaD
Tolmetin—PTGS1—skin of body—systemic scleroderma	0.000759	0.0155	CbGeAlD
Tolmetin—Toxic epidermal necrolysis—Leflunomide—systemic scleroderma	0.000759	0.00567	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Lisinopril—systemic scleroderma	0.000748	0.00559	CcSEcCtD
Tolmetin—Gastritis—Leflunomide—systemic scleroderma	0.000746	0.00557	CcSEcCtD
Tolmetin—Lymphadenopathy—Mycophenolate mofetil—systemic scleroderma	0.000744	0.00555	CcSEcCtD
Tolmetin—Abdominal discomfort—Azathioprine—systemic scleroderma	0.00074	0.00552	CcSEcCtD
Tolmetin—Agranulocytosis—Captopril—systemic scleroderma	0.000736	0.00549	CcSEcCtD
Tolmetin—PTGS2—smooth muscle tissue—systemic scleroderma	0.000735	0.0151	CbGeAlD
Tolmetin—PTGS2—skin of body—systemic scleroderma	0.000726	0.0149	CbGeAlD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.000716	0.0128	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000714	0.0127	CbGpPWpGaD
Tolmetin—Gastritis—Mycophenolic acid—systemic scleroderma	0.000712	0.00531	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—RHOB—systemic scleroderma	0.000712	0.0127	CbGpPWpGaD
Tolmetin—Hepatitis—Captopril—systemic scleroderma	0.000708	0.00528	CcSEcCtD
Tolmetin—Haemolytic anaemia—Mycophenolate mofetil—systemic scleroderma	0.000703	0.00525	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.0007	0.0125	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Mycophenolate mofetil—systemic scleroderma	0.0007	0.00522	CcSEcCtD
Tolmetin—Chest pain—Pentoxifylline—systemic scleroderma	0.000692	0.00517	CcSEcCtD
Tolmetin—Dysuria—Leflunomide—systemic scleroderma	0.000681	0.00509	CcSEcCtD
Tolmetin—Visual disturbance—Mycophenolate mofetil—systemic scleroderma	0.00067	0.005	CcSEcCtD
Tolmetin—Erythema multiforme—Captopril—systemic scleroderma	0.000669	0.00499	CcSEcCtD
Tolmetin—Oedema—Pentoxifylline—systemic scleroderma	0.000663	0.00495	CcSEcCtD
Tolmetin—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.000663	0.00495	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.000662	0.0118	CbGpPWpGaD
Tolmetin—Weight decreased—Leflunomide—systemic scleroderma	0.000659	0.00492	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000655	0.0117	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Lisinopril—systemic scleroderma	0.000652	0.00487	CcSEcCtD
Tolmetin—Dysuria—Mycophenolic acid—systemic scleroderma	0.00065	0.00485	CcSEcCtD
Tolmetin—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.000649	0.00485	CcSEcCtD
Tolmetin—MPO—IL23-mediated signaling events—IL1B—systemic scleroderma	0.000642	0.0115	CbGpPWpGaD
Tolmetin—Agranulocytosis—Azathioprine—systemic scleroderma	0.000642	0.00479	CcSEcCtD
Tolmetin—Gastritis—Lisinopril—systemic scleroderma	0.000641	0.00479	CcSEcCtD
Tolmetin—Renal failure—Leflunomide—systemic scleroderma	0.000639	0.00477	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—CTLA4—systemic scleroderma	0.000637	0.0114	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000635	0.00474	CcSEcCtD
Tolmetin—Stomatitis—Leflunomide—systemic scleroderma	0.000633	0.00473	CcSEcCtD
Tolmetin—Weight increased—Mycophenolic acid—systemic scleroderma	0.000633	0.00472	CcSEcCtD
Tolmetin—Urinary tract infection—Leflunomide—systemic scleroderma	0.000631	0.00471	CcSEcCtD
Tolmetin—Weight decreased—Mycophenolic acid—systemic scleroderma	0.000629	0.00469	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000628	0.0112	CbGpPWpGaD
Tolmetin—Haematuria—Leflunomide—systemic scleroderma	0.000619	0.00462	CcSEcCtD
Tolmetin—Epistaxis—Leflunomide—systemic scleroderma	0.000613	0.00457	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—MMP2—systemic scleroderma	0.000611	0.0109	CbGpPWpGaD
Tolmetin—Renal failure—Mycophenolic acid—systemic scleroderma	0.000609	0.00455	CcSEcCtD
Tolmetin—PTGS1—digestive system—systemic scleroderma	0.000607	0.0124	CbGeAlD
Tolmetin—Agranulocytosis—Leflunomide—systemic scleroderma	0.000606	0.00453	CcSEcCtD
Tolmetin—Stomatitis—Mycophenolic acid—systemic scleroderma	0.000604	0.00451	CcSEcCtD
Tolmetin—Urinary tract infection—Mycophenolic acid—systemic scleroderma	0.000602	0.0045	CcSEcCtD
Tolmetin—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.0006	0.0107	CbGpPWpGaD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000598	0.0107	CbGpPWpGaD
Tolmetin—Chest pain—Mometasone—systemic scleroderma	0.000597	0.00446	CcSEcCtD
Tolmetin—Haematuria—Mycophenolic acid—systemic scleroderma	0.000591	0.00441	CcSEcCtD
Tolmetin—Somnolence—Pentoxifylline—systemic scleroderma	0.00059	0.0044	CcSEcCtD
Tolmetin—Dysuria—Lisinopril—systemic scleroderma	0.000585	0.00437	CcSEcCtD
Tolmetin—Epistaxis—Mycophenolic acid—systemic scleroderma	0.000585	0.00436	CcSEcCtD
Tolmetin—Dyspepsia—Pentoxifylline—systemic scleroderma	0.000584	0.00436	CcSEcCtD
Tolmetin—Erythema multiforme—Azathioprine—systemic scleroderma	0.000584	0.00436	CcSEcCtD
Tolmetin—Hepatitis—Leflunomide—systemic scleroderma	0.000583	0.00435	CcSEcCtD
Tolmetin—PTGS2—digestive system—systemic scleroderma	0.000581	0.0119	CbGeAlD
Tolmetin—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.000578	0.00432	CcSEcCtD
Tolmetin—PTGS1—tendon—systemic scleroderma	0.000578	0.0118	CbGeAlD
Tolmetin—Anaphylactic shock—Mometasone—systemic scleroderma	0.000572	0.00427	CcSEcCtD
Tolmetin—Weight increased—Lisinopril—systemic scleroderma	0.00057	0.00425	CcSEcCtD
Tolmetin—Constipation—Pentoxifylline—systemic scleroderma	0.000567	0.00423	CcSEcCtD
Tolmetin—Weight decreased—Lisinopril—systemic scleroderma	0.000566	0.00423	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—systemic scleroderma	0.000564	0.00421	CcSEcCtD
Tolmetin—Gastritis—Mycophenolate mofetil—systemic scleroderma	0.000562	0.00419	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.00056	0.01	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000559	0.00999	CbGpPWpGaD
Tolmetin—Hepatitis—Mycophenolic acid—systemic scleroderma	0.000556	0.00415	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—systemic scleroderma	0.000556	0.00415	CcSEcCtD
Tolmetin—PTGS2—tendon—systemic scleroderma	0.000553	0.0113	CbGeAlD
Tolmetin—CXCL8—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000552	0.00985	CbGpPWpGaD
Tolmetin—Erythema multiforme—Leflunomide—systemic scleroderma	0.000551	0.00412	CcSEcCtD
Tolmetin—Renal failure—Lisinopril—systemic scleroderma	0.000549	0.0041	CcSEcCtD
Tolmetin—Urinary tract infection—Lisinopril—systemic scleroderma	0.000543	0.00405	CcSEcCtD
Tolmetin—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000542	0.00405	CcSEcCtD
Tolmetin—Glossitis—Methotrexate—systemic scleroderma	0.000537	0.00401	CcSEcCtD
Tolmetin—Visual impairment—Mycophenolic acid—systemic scleroderma	0.000536	0.004	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—CCL2—systemic scleroderma	0.000533	0.00952	CbGpPWpGaD
Tolmetin—Haematuria—Lisinopril—systemic scleroderma	0.000532	0.00397	CcSEcCtD
Tolmetin—Urticaria—Pentoxifylline—systemic scleroderma	0.000527	0.00393	CcSEcCtD
Tolmetin—Epistaxis—Lisinopril—systemic scleroderma	0.000526	0.00393	CcSEcCtD
Tolmetin—Chest pain—Captopril—systemic scleroderma	0.000524	0.00391	CcSEcCtD
Tolmetin—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000524	0.00391	CcSEcCtD
Tolmetin—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000524	0.00391	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000524	0.00936	CbGpPWpGaD
Tolmetin—Agranulocytosis—Lisinopril—systemic scleroderma	0.000521	0.00389	CcSEcCtD
Tolmetin—Tinnitus—Mycophenolic acid—systemic scleroderma	0.000519	0.00387	CcSEcCtD
Tolmetin—Dysuria—Mycophenolate mofetil—systemic scleroderma	0.000513	0.00383	CcSEcCtD
Tolmetin—PTGS1—lung—systemic scleroderma	0.000507	0.0104	CbGeAlD
Tolmetin—Dyspepsia—Mometasone—systemic scleroderma	0.000504	0.00376	CcSEcCtD
Tolmetin—Anaphylactic shock—Captopril—systemic scleroderma	0.000503	0.00375	CcSEcCtD
Tolmetin—Hepatitis—Lisinopril—systemic scleroderma	0.000501	0.00374	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000501	0.00894	CbGpPWpGaD
Tolmetin—Flatulence—Leflunomide—systemic scleroderma	0.0005	0.00373	CcSEcCtD
Tolmetin—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.000499	0.00373	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL1A—systemic scleroderma	0.000498	0.00889	CbGpPWpGaD
Tolmetin—MPO—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000497	0.00887	CbGpPWpGaD
Tolmetin—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.000496	0.0037	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—CD40LG—systemic scleroderma	0.000495	0.00884	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Captopril—systemic scleroderma	0.000492	0.00367	CcSEcCtD
Tolmetin—PTGS2—lung—systemic scleroderma	0.000485	0.00993	CbGeAlD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.000484	0.00863	CbGpPWpGaD
Tolmetin—Vascular purpura—Prednisone—systemic scleroderma	0.000481	0.00359	CcSEcCtD
Tolmetin—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.000481	0.00359	CcSEcCtD
Tolmetin—Flatulence—Mycophenolic acid—systemic scleroderma	0.000477	0.00356	CcSEcCtD
Tolmetin—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000477	0.00356	CcSEcCtD
Tolmetin—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.000476	0.0085	CbGpPWpGaD
Tolmetin—Asthenia—Pentoxifylline—systemic scleroderma	0.000476	0.00355	CcSEcCtD
Tolmetin—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000475	0.00355	CcSEcCtD
Tolmetin—Cardiac failure congestive—Prednisone—systemic scleroderma	0.000474	0.00354	CcSEcCtD
Tolmetin—Erythema multiforme—Lisinopril—systemic scleroderma	0.000474	0.00354	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000468	0.00349	CcSEcCtD
Tolmetin—Tinnitus—Lisinopril—systemic scleroderma	0.000467	0.00349	CcSEcCtD
Tolmetin—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000466	0.00348	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000464	0.00828	CbGpPWpGaD
Tolmetin—Epistaxis—Mycophenolate mofetil—systemic scleroderma	0.000461	0.00344	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000459	0.0082	CbGpPWpGaD
Tolmetin—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00341	CcSEcCtD
Tolmetin—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000454	0.00339	CcSEcCtD
Tolmetin—Body temperature increased—Mometasone—systemic scleroderma	0.000452	0.00338	CcSEcCtD
Tolmetin—Abdominal pain—Mometasone—systemic scleroderma	0.000452	0.00338	CcSEcCtD
Tolmetin—CXCL8—Chemokine receptors bind chemokines—CCL2—systemic scleroderma	0.000451	0.00805	CbGpPWpGaD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—systemic scleroderma	0.000449	0.00802	CbGpPWpGaD
Tolmetin—Somnolence—Captopril—systemic scleroderma	0.000447	0.00334	CcSEcCtD
Tolmetin—Purpura—Prednisone—systemic scleroderma	0.000446	0.00333	CcSEcCtD
Tolmetin—Dyspepsia—Captopril—systemic scleroderma	0.000442	0.0033	CcSEcCtD
Tolmetin—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.000439	0.00328	CcSEcCtD
Tolmetin—Dizziness—Pentoxifylline—systemic scleroderma	0.000439	0.00327	CcSEcCtD
Tolmetin—Chest pain—Leflunomide—systemic scleroderma	0.000432	0.00323	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.00043	0.00321	CcSEcCtD
Tolmetin—Constipation—Captopril—systemic scleroderma	0.00043	0.00321	CcSEcCtD
Tolmetin—Flatulence—Lisinopril—systemic scleroderma	0.00043	0.00321	CcSEcCtD
Tolmetin—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00043	0.00321	CcSEcCtD
Tolmetin—MPO—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000423	0.00756	CbGpPWpGaD
Tolmetin—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000423	0.00316	CcSEcCtD
Tolmetin—Vomiting—Pentoxifylline—systemic scleroderma	0.000422	0.00315	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—systemic scleroderma	0.000421	0.00315	CcSEcCtD
Tolmetin—Headache—Pentoxifylline—systemic scleroderma	0.000416	0.0031	CcSEcCtD
Tolmetin—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000414	0.00309	CcSEcCtD
Tolmetin—Chest pain—Mycophenolic acid—systemic scleroderma	0.000412	0.00308	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000411	0.00735	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Captopril—systemic scleroderma	0.000411	0.00307	CcSEcCtD
Tolmetin—Asthenia—Mometasone—systemic scleroderma	0.000411	0.00307	CcSEcCtD
Tolmetin—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000409	0.00306	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000409	0.0073	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000406	0.00303	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—IL1B—systemic scleroderma	0.000404	0.00722	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000402	0.00718	CbGpPWpGaD
Tolmetin—Abdominal pain—Captopril—systemic scleroderma	0.000397	0.00297	CcSEcCtD
Tolmetin—Body temperature increased—Captopril—systemic scleroderma	0.000397	0.00297	CcSEcCtD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—IL1A—systemic scleroderma	0.000397	0.00708	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000397	0.00708	CbGpPWpGaD
Tolmetin—Oedema—Mycophenolic acid—systemic scleroderma	0.000395	0.00295	CcSEcCtD
Tolmetin—Nausea—Pentoxifylline—systemic scleroderma	0.000394	0.00294	CcSEcCtD
Tolmetin—Diarrhoea—Mometasone—systemic scleroderma	0.000392	0.00292	CcSEcCtD
Tolmetin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000387	0.00289	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000386	0.00689	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—MMP2—systemic scleroderma	0.000386	0.00688	CbGpPWpGaD
Tolmetin—Visual disturbance—Methotrexate—systemic scleroderma	0.000379	0.00283	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—TGFB1—systemic scleroderma	0.000378	0.00676	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000377	0.00674	CbGpPWpGaD
Tolmetin—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000377	0.00281	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000375	0.00669	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000371	0.00277	CcSEcCtD
Tolmetin—Chest pain—Lisinopril—systemic scleroderma	0.000371	0.00277	CcSEcCtD
Tolmetin—Dyspepsia—Leflunomide—systemic scleroderma	0.000365	0.00272	CcSEcCtD
Tolmetin—Vomiting—Mometasone—systemic scleroderma	0.000364	0.00272	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—IL1A—systemic scleroderma	0.000361	0.00645	CbGpPWpGaD
Tolmetin—Asthenia—Captopril—systemic scleroderma	0.000361	0.00269	CcSEcCtD
Tolmetin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000359	0.00268	CcSEcCtD
Tolmetin—Headache—Mometasone—systemic scleroderma	0.000359	0.00268	CcSEcCtD
Tolmetin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000356	0.00266	CcSEcCtD
Tolmetin—Oedema—Lisinopril—systemic scleroderma	0.000356	0.00266	CcSEcCtD
Tolmetin—Constipation—Leflunomide—systemic scleroderma	0.000354	0.00264	CcSEcCtD
Tolmetin—Somnolence—Mycophenolic acid—systemic scleroderma	0.000351	0.00262	CcSEcCtD
Tolmetin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000349	0.0026	CcSEcCtD
Tolmetin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000348	0.0026	CcSEcCtD
Tolmetin—Abdominal pain—Azathioprine—systemic scleroderma	0.000347	0.00259	CcSEcCtD
Tolmetin—Body temperature increased—Azathioprine—systemic scleroderma	0.000347	0.00259	CcSEcCtD
Tolmetin—CXCL8—Unfolded Protein Response (UPR)—CCL2—systemic scleroderma	0.000346	0.00618	CbGpPWpGaD
Tolmetin—Diarrhoea—Captopril—systemic scleroderma	0.000344	0.00257	CcSEcCtD
Tolmetin—Nausea—Mometasone—systemic scleroderma	0.00034	0.00254	CcSEcCtD
Tolmetin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000339	0.00253	CcSEcCtD
Tolmetin—Weight increased—Prednisone—systemic scleroderma	0.000338	0.00253	CcSEcCtD
Tolmetin—Constipation—Mycophenolic acid—systemic scleroderma	0.000338	0.00252	CcSEcCtD
Tolmetin—Weight decreased—Prednisone—systemic scleroderma	0.000336	0.00251	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000334	0.00596	CbGpPWpGaD
Tolmetin—Dizziness—Captopril—systemic scleroderma	0.000332	0.00248	CcSEcCtD
Tolmetin—Urticaria—Leflunomide—systemic scleroderma	0.000329	0.00246	CcSEcCtD
Tolmetin—Abdominal pain—Leflunomide—systemic scleroderma	0.000328	0.00245	CcSEcCtD
Tolmetin—Body temperature increased—Leflunomide—systemic scleroderma	0.000328	0.00245	CcSEcCtD
Tolmetin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000325	0.00243	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000324	0.00242	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000323	0.00241	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000322	0.00576	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000321	0.00574	CbGpPWpGaD
Tolmetin—Vomiting—Captopril—systemic scleroderma	0.00032	0.00239	CcSEcCtD
Tolmetin—Somnolence—Lisinopril—systemic scleroderma	0.000316	0.00236	CcSEcCtD
Tolmetin—Headache—Captopril—systemic scleroderma	0.000315	0.00235	CcSEcCtD
Tolmetin—Dyspepsia—Lisinopril—systemic scleroderma	0.000313	0.00234	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000313	0.00558	CbGpPWpGaD
Tolmetin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000312	0.00233	CcSEcCtD
Tolmetin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000312	0.00233	CcSEcCtD
Tolmetin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000312	0.00233	CcSEcCtD
Tolmetin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000312	0.00233	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000312	0.00557	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000308	0.00549	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000305	0.00228	CcSEcCtD
Tolmetin—Constipation—Lisinopril—systemic scleroderma	0.000304	0.00227	CcSEcCtD
Tolmetin—Diarrhoea—Azathioprine—systemic scleroderma	0.0003	0.00224	CcSEcCtD
Tolmetin—Nausea—Captopril—systemic scleroderma	0.000299	0.00223	CcSEcCtD
Tolmetin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000298	0.00222	CcSEcCtD
Tolmetin—Asthenia—Leflunomide—systemic scleroderma	0.000297	0.00222	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000296	0.00528	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000291	0.00217	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—systemic scleroderma	0.000291	0.00217	CcSEcCtD
Tolmetin—Dizziness—Azathioprine—systemic scleroderma	0.00029	0.00217	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—MMP9—systemic scleroderma	0.00029	0.00517	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000289	0.00516	CbGpPWpGaD
Tolmetin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000284	0.00212	CcSEcCtD
Tolmetin—Diarrhoea—Leflunomide—systemic scleroderma	0.000283	0.00212	CcSEcCtD
Tolmetin—Urticaria—Lisinopril—systemic scleroderma	0.000283	0.00211	CcSEcCtD
Tolmetin—Abdominal pain—Lisinopril—systemic scleroderma	0.000281	0.0021	CcSEcCtD
Tolmetin—Body temperature increased—Lisinopril—systemic scleroderma	0.000281	0.0021	CcSEcCtD
Tolmetin—Vomiting—Azathioprine—systemic scleroderma	0.000279	0.00208	CcSEcCtD
Tolmetin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000277	0.00207	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—systemic scleroderma	0.000277	0.00207	CcSEcCtD
Tolmetin—Headache—Azathioprine—systemic scleroderma	0.000275	0.00205	CcSEcCtD
Tolmetin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00205	CcSEcCtD
Tolmetin—Dizziness—Leflunomide—systemic scleroderma	0.000274	0.00205	CcSEcCtD
Tolmetin—Renal failure—Methotrexate—systemic scleroderma	0.000272	0.00203	CcSEcCtD
Tolmetin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00027	0.00202	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.00027	0.00482	CbGpPWpGaD
Tolmetin—Stomatitis—Methotrexate—systemic scleroderma	0.00027	0.00202	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—MMP9—systemic scleroderma	0.00027	0.00482	CbGpPWpGaD
Tolmetin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000267	0.00199	CcSEcCtD
Tolmetin—Haematuria—Methotrexate—systemic scleroderma	0.000264	0.00197	CcSEcCtD
Tolmetin—Vomiting—Leflunomide—systemic scleroderma	0.000263	0.00197	CcSEcCtD
Tolmetin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000261	0.00195	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—systemic scleroderma	0.000261	0.00195	CcSEcCtD
Tolmetin—Nausea—Azathioprine—systemic scleroderma	0.000261	0.00195	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL1B—systemic scleroderma	0.00026	0.00464	CbGpPWpGaD
Tolmetin—Headache—Leflunomide—systemic scleroderma	0.00026	0.00194	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—systemic scleroderma	0.000259	0.00193	CcSEcCtD
Tolmetin—Asthenia—Lisinopril—systemic scleroderma	0.000255	0.00191	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000255	0.0019	CcSEcCtD
Tolmetin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000251	0.00188	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—IL1A—systemic scleroderma	0.000251	0.00448	CbGpPWpGaD
Tolmetin—Hepatitis—Methotrexate—systemic scleroderma	0.000249	0.00186	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—CCL2—systemic scleroderma	0.000248	0.00444	CbGpPWpGaD
Tolmetin—CXCL8—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000248	0.00443	CbGpPWpGaD
Tolmetin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00185	CcSEcCtD
Tolmetin—Headache—Mycophenolic acid—systemic scleroderma	0.000248	0.00185	CcSEcCtD
Tolmetin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00184	CcSEcCtD
Tolmetin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00184	CcSEcCtD
Tolmetin—Nausea—Leflunomide—systemic scleroderma	0.000246	0.00184	CcSEcCtD
Tolmetin—Diarrhoea—Lisinopril—systemic scleroderma	0.000244	0.00182	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000242	0.00433	CbGpPWpGaD
Tolmetin—Visual impairment—Methotrexate—systemic scleroderma	0.00024	0.00179	CcSEcCtD
Tolmetin—Dizziness—Lisinopril—systemic scleroderma	0.000235	0.00176	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—systemic scleroderma	0.000235	0.00176	CcSEcCtD
Tolmetin—Nausea—Mycophenolic acid—systemic scleroderma	0.000235	0.00175	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—systemic scleroderma	0.000232	0.00173	CcSEcCtD
Tolmetin—Vomiting—Lisinopril—systemic scleroderma	0.000226	0.00169	CcSEcCtD
Tolmetin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00167	CcSEcCtD
Tolmetin—Headache—Lisinopril—systemic scleroderma	0.000223	0.00166	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.000222	0.00397	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—HSPG2—systemic scleroderma	0.000218	0.00389	CbGpPWpGaD
Tolmetin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000213	0.00159	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000212	0.00378	CbGpPWpGaD
Tolmetin—Nausea—Lisinopril—systemic scleroderma	0.000211	0.00158	CcSEcCtD
Tolmetin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000211	0.00158	CcSEcCtD
Tolmetin—Oedema—Prednisone—systemic scleroderma	0.000211	0.00158	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000207	0.00369	CbGpPWpGaD
Tolmetin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000206	0.00154	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—TGFB1—systemic scleroderma	0.000202	0.0036	CbGpPWpGaD
Tolmetin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000198	0.00148	CcSEcCtD
Tolmetin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00146	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—IL1A—systemic scleroderma	0.00019	0.00339	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—IL1B—systemic scleroderma	0.000188	0.00336	CbGpPWpGaD
Tolmetin—Dyspepsia—Prednisone—systemic scleroderma	0.000186	0.00139	CcSEcCtD
Tolmetin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000185	0.00138	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—systemic scleroderma	0.000184	0.00138	CcSEcCtD
Tolmetin—Constipation—Prednisone—systemic scleroderma	0.000181	0.00135	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000179	0.00319	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—MMP9—systemic scleroderma	0.000178	0.00317	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000177	0.00132	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000173	0.0031	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000173	0.00129	CcSEcCtD
Tolmetin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000173	0.00129	CcSEcCtD
Tolmetin—CXCL8—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00017	0.00303	CbGpPWpGaD
Tolmetin—Urticaria—Prednisone—systemic scleroderma	0.000168	0.00125	CcSEcCtD
Tolmetin—Body temperature increased—Prednisone—systemic scleroderma	0.000167	0.00125	CcSEcCtD
Tolmetin—Abdominal pain—Prednisone—systemic scleroderma	0.000167	0.00125	CcSEcCtD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000166	0.00297	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000165	0.00295	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—CTGF—systemic scleroderma	0.000165	0.00295	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000161	0.00287	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000158	0.00283	CbGpPWpGaD
Tolmetin—Somnolence—Methotrexate—systemic scleroderma	0.000157	0.00117	CcSEcCtD
Tolmetin—Dyspepsia—Methotrexate—systemic scleroderma	0.000156	0.00116	CcSEcCtD
Tolmetin—Asthenia—Prednisone—systemic scleroderma	0.000152	0.00113	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000151	0.00269	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000146	0.00261	CbGpPWpGaD
Tolmetin—Diarrhoea—Prednisone—systemic scleroderma	0.000145	0.00108	CcSEcCtD
Tolmetin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000144	0.00108	CcSEcCtD
Tolmetin—Urticaria—Methotrexate—systemic scleroderma	0.00014	0.00105	CcSEcCtD
Tolmetin—CXCL8—GPCR downstream signaling—RHOB—systemic scleroderma	0.00014	0.00251	CbGpPWpGaD
Tolmetin—Dizziness—Prednisone—systemic scleroderma	0.00014	0.00104	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—systemic scleroderma	0.00014	0.00104	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—systemic scleroderma	0.00014	0.00104	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000138	0.00246	CbGpPWpGaD
Tolmetin—Vomiting—Prednisone—systemic scleroderma	0.000134	0.001	CcSEcCtD
Tolmetin—Headache—Prednisone—systemic scleroderma	0.000132	0.000989	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000131	0.00235	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—RHOB—systemic scleroderma	0.000127	0.00228	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—EDN1—systemic scleroderma	0.000127	0.00226	CbGpPWpGaD
Tolmetin—Asthenia—Methotrexate—systemic scleroderma	0.000127	0.000946	CcSEcCtD
Tolmetin—Nausea—Prednisone—systemic scleroderma	0.000126	0.000938	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—systemic scleroderma	0.000121	0.000903	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—systemic scleroderma	0.000117	0.000872	CcSEcCtD
Tolmetin—CXCL8—Metabolism of proteins—ACE—systemic scleroderma	0.000117	0.00209	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000114	0.00203	CbGpPWpGaD
Tolmetin—Vomiting—Methotrexate—systemic scleroderma	0.000112	0.000839	CcSEcCtD
Tolmetin—Headache—Methotrexate—systemic scleroderma	0.000111	0.000826	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000109	0.00194	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000105	0.00188	CbGpPWpGaD
Tolmetin—Nausea—Methotrexate—systemic scleroderma	0.000105	0.000784	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000104	0.00186	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SMAD7—systemic scleroderma	9.73e-05	0.00174	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—CCL2—systemic scleroderma	8.67e-05	0.00155	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.35e-05	0.00149	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	8.25e-05	0.00147	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.97e-05	0.00142	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	7.78e-05	0.00139	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—RHOB—systemic scleroderma	7.53e-05	0.00134	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—MMP1—systemic scleroderma	7.5e-05	0.00134	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—NOS3—systemic scleroderma	7.19e-05	0.00128	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—EDN1—systemic scleroderma	7.16e-05	0.00128	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HSPG2—systemic scleroderma	7.1e-05	0.00127	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CSK—systemic scleroderma	6.86e-05	0.00122	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—EDN1—systemic scleroderma	6.51e-05	0.00116	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	6.41e-05	0.00115	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.33e-05	0.00113	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—CCL2—systemic scleroderma	6.1e-05	0.00109	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SMAD7—systemic scleroderma	6.09e-05	0.00109	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—MMP2—systemic scleroderma	5.8e-05	0.00104	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TGFBI—systemic scleroderma	5.57e-05	0.000994	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HSPG2—systemic scleroderma	4.68e-05	0.000837	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—CCL2—systemic scleroderma	4.45e-05	0.000794	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HSPG2—systemic scleroderma	4.44e-05	0.000793	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.36e-05	0.000779	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CSK—systemic scleroderma	4.29e-05	0.000766	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CD247—systemic scleroderma	4.03e-05	0.00072	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EDN1—systemic scleroderma	3.84e-05	0.000686	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HSPG2—systemic scleroderma	3.72e-05	0.000664	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CTGF—systemic scleroderma	3.55e-05	0.000634	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CTGF—systemic scleroderma	2.82e-05	0.000503	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CCL2—systemic scleroderma	2.63e-05	0.000469	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NOS3—systemic scleroderma	2.34e-05	0.000418	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MMP9—systemic scleroderma	1.88e-05	0.000336	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TGFB1—systemic scleroderma	1.55e-05	0.000277	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NOS3—systemic scleroderma	1.55e-05	0.000276	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NOS3—systemic scleroderma	1.46e-05	0.000262	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NOS3—systemic scleroderma	1.23e-05	0.000219	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TGFB1—systemic scleroderma	9.69e-06	0.000173	CbGpPWpGaD
